skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

ファーマインテリジェンスはInforma PLCのインフォーマインテリジェンス部門の一部です

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon レポートストアメルマガ登録製品ログインProductLogin
Global Search Configuration
  • Close Icon

About Daniel

+11 year(s) experience

Daniel Chancellor - Pharmaintelligence
Director Daniel Chancellor analyzes and forecasts drug markets for neurology, psychiatry, and rare diseases.

He stays abreast of market developments, generating and curating data sources, and distilling these into reports that enable clients to gain a competitive edge.

Since joining Pharma Intelligence in 2010, Daniel has tracked and forecast all the leading neurology, psychiatry, and pain drug markets. He is particularly interested in the shifting landscape of the multiple sclerosis market well as the implications of trial failures – alongside the successes in Alzheimer's disease R&D.

He has helped expand research and insight on rare diseases , including established orphan drug markets as well as as emerging opportunities. He also attends international medical conferences and enjoys collaborating with colleagues at Scrip.

Daniel has a First Class degree in Natural Sciences from the University of Bath.


Specialties

  • CNS
  • Rare Diseases
  • Psychiatry
  • Neurology

Daniel Writes For

Analyst Articles

Articles by Neena